COPD

Latest News


Type 2 Inflammation: A Common Theme Among Several Chronic Diseases

Learn about the multifaceted aspects of type 2 inflammatory diseases, including impact on quality of life; the role of biomarkers in diagnosis and treatment selection; and unmet needs in clinical management.

Type 2 Inflammation: A Common Theme Among Several Chronic Diseases

CME Content


Oral theophylline has been used as a bronchodilator to treat chronic obstructive pulmonary disease (COPD) for decades, but it has fallen out of favor due to the side effects that come with the higher doses that are required to achieve any beneficial effect. A recent study sought to determine if adding low-dose theophylline to inhaled corticosteroids for COPD would reduce the number of exacerbations.

A recent study determined that patients with chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) had similar tumor microenvironment, but higher tumor infiltrating lymphocytes (TIL) exhaustion, than patients without COPD. The use of an anti-programmed cell death-1 (PD-1) antibody, nivolumab, was also demonstrated to be effective in this population.

Some patients with chronic obstructive pulmonary disease (COPD) experience a sudden worsening of their symptoms that require additional treatment—also known as acute exacerbation of COPD (AECOPD). A recent study, which investigated whether readmissions of patients with severe AECOPD varied according to the bacterium or virus identified, found that P. aeruginosa identification is associated with a higher readmission rate in patients.

Previous phase 3 studies have demonstrated the efficacy of nebulized glycopyrrolate inhalation solution (GLY) for treating patients with chronic obstructive pulmonary disease (COPD). In a recent study, researchers conducted a secondary analysis and found that nebulized GLY demonstrated efficacy and was well tolerated for up to 48 weeks in subjects with COPD with or without background long-acting beta2-agonist (LABA).

Patients with chronic obstructive pulmonary disease (COPD) often have a significant disease burden that is particularly associated with the peak incidence of exacerbation events during winter months. A review assessed previous population studies that evaluated the impact of seasonality in COPD, emphasizing the importance of understanding how all factors impact patients and where interventions can be targeted.

There is an increased need for potential biomarkers that can identify patients with chronic obstructive pulmonary disease (COPD) who will benefit from treatment involving inhaled corticosteroids (ICS). According to a recent study, the 2% threshold for blood eosinophils could accurately predict ICS treatment response in patients with COPD, but the risk of pneumonia was increased.

Telerehabilitation (TR), defined as telecare that involves supervised online exercise sessions for patients with chronic obstructive pulmonary disease (COPD), is beneficial for symptom relief, physical function, and quality of life. A recent study found that specific attention toward the involvement of health professionals in the decision process combined with education and skill training is essential to support the successful implementation of TR.

A study that sought to replicate the effects of vaping on lung cells found that vapor from e-cigarettes boosts the production of inflammatory chemicals and disables key protective cells in the lung that engulf potentially harmful particles. Some of the effects were similar to those seen in regular smokers and people with chronic obstructive pulmonary disease.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo